STEER RANDOLPH C 4
4 · BIO-TECHNE Corp · Filed Nov 10, 2020
Insider Transaction Report
Form 4
BIO-TECHNE CorpTECH
STEER RANDOLPH C
Director
Transactions
- Exercise/Conversion
Common Stock
2020-11-06$66.90/sh+5,000$334,500→ 15,112 total - Sale
Common Stock
2020-11-06$299.96/sh−1,771$531,229→ 11,618 total - Sale
Common Stock
2020-11-06$301.78/sh−1,801$543,506→ 9,817 total - Sale
Common Stock
2020-11-06$304.59/sh−2,535$772,136→ 5,112 total - Sale
Common Stock
2020-11-06$299.06/sh−1,723$515,280→ 13,389 total - Exercise/Conversion
Common Stock
2020-11-06$70.35/sh+5,000$351,750→ 10,112 total - Sale
Common Stock
2020-11-06$302.31/sh−1,195$361,260→ 8,622 total - Sale
Common Stock
2020-11-06$304.14/sh−975$296,537→ 7,647 total - Exercise/Conversion
Stock Option (Right to Buy)
2020-11-06−5,000→ 0 totalExercise: $70.35From: 2011-10-27Exp: 2021-10-26→ Common Stock (5,000 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2020-11-06−5,000→ 0 totalExercise: $66.90From: 2012-10-25Exp: 2022-10-24→ Common Stock (5,000 underlying)
Holdings
- 2,011
Stock Option (Right to Buy)
Exercise: $201.64From: 2020-10-24Exp: 2029-10-24→ Common Stock (2,011 underlying) - 3,125
Stock Option (Right to Buy)
Exercise: $125.05From: 2018-10-25Exp: 2027-10-26→ Common Stock (3,125 underlying) - 4,260
Stock Option (Right to Buy)
Exercise: $87.34From: 2016-10-29Exp: 2025-10-28→ Common Stock (4,260 underlying) - 4,000
Stock Option (Right to Buy)
Exercise: $87.39From: 2013-10-31Exp: 2023-10-30→ Common Stock (4,000 underlying) - 1,507
Stock Option (Right to Buy)
Exercise: $255.69From: 2021-10-29Exp: 2030-10-29→ Common Stock (1,507 underlying) - 1,898
Stock Option (Right to Buy)
Exercise: $179.84From: 2019-10-24Exp: 2028-10-25→ Common Stock (1,898 underlying) - 3,985
Stock Option (Right to Buy)
Exercise: $101.19From: 2017-10-26Exp: 2026-10-26→ Common Stock (3,985 underlying) - 4,000
Stock Option (Right to Buy)
Exercise: $91.78From: 2014-10-30Exp: 2024-10-30→ Common Stock (4,000 underlying)
Footnotes (6)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $298.49 to $299.30, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $299.70 to $300.42, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $301.00 to $301.98, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $302.00 to $302.67, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $303.47 to $304.46, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $304.59 to $304.67, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.